A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats

  • McEachern J
  • Bingham J
  • Crameri G
 et al. 
  • 37

    Readers

    Mendeley users who have this article in their library.
  • 53

    Citations

    Citations of this article.

Abstract

Nipah virus (NiV) and Hendra virus (HeV) are closely related deadly zoonotic paramyxoviruses that have emerged and re-emerged over the last 10 years. In this study, a subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein from HeV (sGHeV) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Different amounts of sGHeVwere employed and sG-induced immunity was examined. Vaccinated animals demonstrated varying levels of NiV-specific Ig systemically and importantly, all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV (50,000 TCID50), all vaccinated animals were protected from disease although virus was detected on day 21 post-challenge in one animal. The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses. © 2008 CSIRO.

Author-supplied keywords

  • CpG
  • Henipavirus
  • Mucosal immunity
  • Subunit vaccine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Jennifer A. McEachern

  • John Bingham

  • Gary Crameri

  • Diane J. Green

  • Tim J. Hancock

  • Deborah Middleton

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free